Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: cotadutide


Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis

May 1st 2022

Cotadutide is safe and effective in reducing plasma glucose levels, HbA1c and body weight in individuals with type 2 diabetes (BMC Endocrine Disorders)

Categories: Medication, News
Tags: cotadutide, Type 2 Diabetes

Categories: Medication
Tags: cotadutide, Type 2 Diabetes

Efficacy and safety of cotadutide, a dual GLP-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease

April 12th 2022

We established the efficacy of cotadutide in this patient population, with significantly improved postprandial glucose control and reduced bodyweight versus placebo. Reductions in UACR suggest potential benefits of cotadutide on kidney function, supporting further evaluation in larger, longer-term clinical trials (Diabetes, Obesity and Metabolism)

Categories: Medication, Nephropathy, News
Tags: CKD, cotadutide, Type 2 Diabetes

Categories: Medication, Nephropathy
Tags: CKD, cotadutide, Type 2 Diabetes

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Novo NordiskBoehringer IngelheimAstraZenecaNapp Diabetes

Silver Sponsors

About Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors elderly Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership